SNS 314

Drug Profile

SNS 314

Alternative Names: SNS-314

Latest Information Update: 01 Feb 2011

Price : $50

At a glance

  • Originator Sunesis Pharmaceuticals
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors; Aurora kinase B inhibitors; Aurora kinase C inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Suspended Solid tumours

Most Recent Events

  • 26 Jan 2011 CyDex Pharmaceuticals has been acquired by Ligand Pharmaceuticals
  • 05 Mar 2009 Sunesis completes a phase I trial in Solid tumours in USA
  • 24 Oct 2008 Interim adverse events, pharmacodynamics and pharmacokinetics data from a phase I trial in advanced solid tumours presented at the 20th-EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics (EORTC-NCI-AACR-2008) ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top